Synthetic Data in Pharma R&D: Use Cases, Risks, and Governance

What Synthetic Data Actually Is in Pharma Context

“Synthetic data” is not one thing. In pharma R&D it covers at least four distinct technical approaches with different statistical properties, governance implications, and acceptable use boundaries. Treating them as interchangeable is the first governance failure most organizations make.

The first category is simulated data — data generated by mechanistic or process models that don’t ingest real patient information. Quantitative systems pharmacology models, pharmacokinetic simulations, and trial simulations fall here. The data is synthetic in the sense that no real patient produced it, but the statistical fidelity to real-world distributions varies widely depending on model maturity and use case.

The second category is statistically generated data — datasets produced from summary statistics, distributions, or correlation matrices derived from real data. The output preserves certain statistical properties of the source while not reproducing individual records. This category is most familiar to biostatisticians and has a long history in pharma; what’s new is the scale at which it can now be produced.

The third category is generative model-produced data — datasets produced by deep learning models trained on real patient data, including generative adversarial networks (GANs), variational autoencoders, and increasingly large language models adapted to structured medical data. This category produces the most realistic synthetic data and also carries the most complex risk profile because the model has actually seen real patient records.

The fourth category is privacy-preserving synthetic data — data generated under formal privacy guarantees (typically differential privacy) that mathematically bound the information any synthetic record can reveal about any real source record. This category is the most defensible from a privacy perspective and is the direction the regulatory conversation is increasingly heading.

Pharma R&D programs frequently use multiple categories simultaneously, often without distinguishing them in governance documentation. Inspectors and regulators have started asking which category a given synthetic dataset belongs to and what privacy and validity properties it has — questions most pharma documentation isn’t currently structured to answer.

Use Cases That Are Working

The use cases where synthetic data is delivering measurable value in pharma R&D today are well-defined enough to support investment decisions. The use cases that look promising but haven’t yet proven out are still worth tracking, but the operational case for them is weaker.

The high-maturity use cases — software development, cross-border collaboration — have well-developed practices, mature tooling, and regulatory acceptance. The medium-maturity use cases — trial simulation, external control arms, AI model training — are operationally viable but require careful per-application validation and explicit regulatory engagement. The lower-maturity use cases are worth piloting but shouldn’t yet bear material weight in decisions with regulatory or patient-impact dimensions.

The use case that’s getting the most regulatory attention is external control arms in rare disease trials. The clinical opportunity is real — rare disease trials struggle to recruit, control arms are ethically and operationally challenging, and synthetic external controls offer a path to meaningful efficacy assessment with smaller real-patient enrollment. The regulatory community is engaging seriously with the methodology, and FDA in particular has signaled willingness to consider synthetic control arms as supportive evidence in well-justified cases. That said, the bar for acceptance is high and the documentation requirements are substantial; organizations pursuing this use case need to engage regulators early rather than late.

The Risks Regulators Actually Care About

The risk conversation in synthetic data has been dominated by two threads — privacy and statistical validity. Both matter. Both are necessary but not sufficient. Three additional risk dimensions deserve more attention than they typically get.

Privacy risk is the most discussed. Synthetic data generated by models trained on real patient data can in principle leak information about real patients, particularly for individuals with rare or distinctive characteristics. The risk is real but bounded — well-designed differential privacy frameworks meaningfully constrain the leakage, and the empirical track record of well-governed synthetic data is good. The risk that’s harder to manage is the unbounded case: synthetic data generated by a model with no formal privacy guarantees, deployed in contexts where the original training source is sensitive.

Statistical validity risk is the next most discussed. Synthetic data that fails to preserve relationships in the source data can produce misleading analyses — particularly for downstream decisions that depend on subgroup behavior, rare event rates, or non-linear interactions. The risk is most acute when synthetic data is used as if it were real data without explicit acknowledgment. Validity risk is best managed through explicit testing of synthetic data against real-data benchmarks for the specific analytical questions the synthetic data will support.

Provenance and reproducibility risk is the third dimension. A synthetic dataset that informs a regulatory decision needs to be reproducibly traceable to its source. If the model that generated it has been retrained, the parameters changed, or the training data updated, the synthetic dataset is effectively a different artifact. Organizations need versioning discipline that treats synthetic datasets as governed objects with full provenance — not as ephemeral outputs of an analytical workflow.

Use-case drift risk is the fourth. Synthetic data generated for one purpose gets quietly reused for another that the original validation didn’t cover. The dataset that was validated for software testing gets used for analytical hypothesis generation; the dataset validated for hypothesis generation gets used for decision support; the decision support dataset gets cited in a regulatory filing. Each step is a small extension; the cumulative drift is significant. Governance has to control reuse explicitly.

Bias amplification risk is the fifth. Synthetic data can preserve or amplify biases in the source data — including biases that the original use case didn’t expose but a downstream use case does. A synthetic dataset produced from a clinical trial population may underrepresent demographic groups in ways that don’t matter for the original analysis but do matter when the dataset is reused to train a clinical AI tool. Bias evaluation has to be use-case specific, not just dataset specific.

Current Regulatory Posture

The current regulatory posture toward synthetic data is best described as constructively cautious. FDA, EMA, MHRA, and PMDA have all engaged with synthetic data publicly, with broadly converging directional positions: synthetic data can be used in pharma R&D and even in regulatory submissions when the methodology is well-justified and the documentation is rigorous, but it is not a shortcut around the standards that would apply to real data.

FDA’s posture in 2025-2026 has been notably constructive. The agency has signaled openness to synthetic external control arms, has engaged with industry consortia on methodology standards, and has issued informal guidance on documentation expectations. The pattern is clear: organizations that engage early, document rigorously, and present scientifically defensible cases get more constructive regulatory dialogue than organizations that try to slip synthetic data into submissions without adequate methodology disclosure.

EMA’s reflection paper on AI in the medicinal product lifecycle covers synthetic data among related topics. The European posture is somewhat more cautious on privacy, given GDPR’s strict standards, and somewhat more open on methodology innovation. Cross-jurisdictional submissions have to navigate both sets of expectations, and the practical answer is to design to the more rigorous standard for any given dimension.

The regulatory direction over the next 18-24 months is likely to involve more specific guidance on documentation expectations, validation methodology, and acceptable use boundaries. Organizations that build governance frameworks now that anticipate the direction — provenance, reproducibility, use-case scoping, privacy guarantees — will find themselves in a stronger position than organizations that wait for guidance to crystallize.

Governance Framework for Synthetic Data

A governance framework for synthetic data needs to address six dimensions explicitly. Frameworks that handle four or five of these well but skip one or two tend to develop the gaps that surface under inspection.

1. Use case classification. Each synthetic data use case gets classified by intended use (development, analytical, decision support, regulatory submission), risk tier, and acceptable boundaries. The classification drives the documentation, validation, and approval requirements.
2. Generation methodology documentation. The technical approach, model architecture, training data, parameters, and validation evidence are documented to a standard appropriate for the use case tier. For high-tier use cases, this documentation should support inspection-readiness.
3. Privacy assessment. Each synthetic dataset gets an explicit privacy risk assessment. For datasets generated from real patient data, the assessment includes the privacy guarantees of the generation method and the residual risk under the intended use.
4. Validity validation. The synthetic dataset is validated against real-data benchmarks for the specific analytical or decision-support questions it will support. The validation is documented, versioned, and reviewed periodically.
5. Provenance and versioning. Synthetic datasets are governed as versioned artifacts with full provenance chains. Reuse outside the original validated scope requires explicit re-validation.
6. Approval workflow. Use cases above defined risk thresholds require approval from a cross-functional governance body that includes data science, biostatistics, privacy, and quality representation.

The governance framework should be lightweight enough to support routine use cases without bottlenecking R&D and rigorous enough to catch the use cases where the stakes warrant scrutiny. Most organizations err on one side or the other — either the framework is so heavy that R&D teams route around it, or so light that high-stakes use cases proceed without adequate review. Calibrating the friction to the risk is the central design challenge.

Validation and Quality Assurance

Validation of synthetic data is methodologically distinct from traditional data validation. The question isn’t whether the data is “correct” — synthetic data is by definition not real — but whether it preserves the properties needed for the intended use. The validation has to be use-case specific.

The validation dimensions that matter most:

• Distributional fidelity for univariate and multivariate distributions in the dimensions the use case depends on
• Relationship preservation for the correlations, interactions, and dependencies the analytical use depends on
• Edge case coverage for the rare events or subpopulations the use case may need to address
• Decision equivalence for use cases where synthetic data informs decisions — does the decision derived from synthetic data match the decision that real data would have produced, within acceptable bounds?
• Privacy validation through formal or empirical testing of re-identification risk
• Bias evaluation against fairness criteria appropriate to the use case

Validation evidence should be documented in a form that supports both internal scientific review and external regulatory inquiry. The documentation should be intelligible to regulators and quality reviewers, not just to the data science team that produced the dataset — a frequent failure mode.

Operating Model and Internal Capability

Building synthetic data capability inside a pharma R&D organization requires deliberate operating model design. The capability lives at the intersection of biostatistics, data science, privacy, and regulatory — and organizations that don’t explicitly orchestrate the intersection tend to produce synthetic data that’s strong on one or two dimensions and weak on others.

The operating model questions that matter most:

• Center of excellence vs. distributed capability. Most large-cap pharma organizations are converging on a hybrid: a central team that develops methodology, governance, and tooling, with distributed practitioners embedded in the functions that use synthetic data routinely.
• Vendor strategy. Several vendors offer synthetic data platforms with varying levels of pharma specialization. Vendor selection should follow the same diligence rigor as other AI vendors — validation evidence, regulatory posture, data handling, and contractual flexibility.
• Skill development. Synthetic data is a specialized skill; pharma organizations consistently underestimate the talent investment required to build durable capability. Hiring, training, and retention of synthetic data practitioners is a multi-year investment.
• Cross-functional governance. The governance body has to include voices from biostatistics, privacy, quality, and regulatory — not just from the technical function generating the data.
• Documentation infrastructure. The provenance, versioning, and validation documentation needs system support, not ad hoc files. Organizations that try to manage synthetic data documentation in shared drives accumulate gaps that surface under inspection.

Where the Field Is Heading

Three directional shifts in the synthetic data landscape over the next 18-24 months will materially affect pharma R&D operating decisions.

First, regulator acceptance is broadening but the documentation bar is rising. The path from “this is novel methodology” to “this is acceptable for submission” is shortening — but it requires more rigorous documentation than many pharma organizations currently produce. The organizations that build documentation capability now will find themselves with a meaningful capability advantage.

Second, foundation model approaches are maturing. Generative models trained on large corpora of structured medical data are producing synthetic datasets with materially better fidelity than the previous generation of GAN-based approaches. The implication: the use cases that synthetic data can credibly support are expanding, but so is the risk surface, and the governance has to keep pace.

Third, the consortium and standards work is accelerating. Industry consortia, regulatory bodies, and standards organizations are converging on methodology standards, validation approaches, and reporting expectations. Organizations that participate in this work shape the standards their R&D will eventually have to meet — and gain early visibility into directional shifts before they crystallize as expectations.

Synthetic data is one of the small number of pharma R&D capabilities where the gap between the leading 20% of organizations and the trailing 80% is widening rather than narrowing. The leaders are building governance, capability, and documentation depth that the trailing organizations will need to acquire under regulatory pressure later. The cost-effective time to build the capability is now, while the operational stakes are still moderate; the cost-ineffective time is when the capability is required for a high-stakes submission and the foundation isn’t ready.

The capability that compounds

One characteristic of synthetic data capability that’s worth recognizing explicitly: it compounds. The methodology investment, governance infrastructure, and documentation depth built for the first use case create leverage for every subsequent use case. The early use cases are expensive per unit of value generated; the later use cases ride on top of accumulated infrastructure at materially lower marginal cost. Organizations that recognize the compounding dynamic invest deliberately in the foundation; organizations that don’t tend to evaluate each use case on its own narrow economics and under-invest in the foundation that would have made the portfolio of use cases viable.

The compounding dynamic also applies to talent. Synthetic data practitioners develop judgment over time that’s hard to short-circuit through hiring alone. Organizations that retain practitioners across multiple use cases, with deliberate development paths and exposure to varied problem types, build deeper bench strength than organizations that staff use cases with rotating contractors or junior practitioners. The talent compounding pays back in the quality of methodology decisions, the speed of new use case execution, and the credibility of regulator engagement.

References